Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Public ClinicalTrials.gov record NCT00003674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients with advanced cancer that has not responded to previous treatment. It is not yet known if standard therapy is more effective with or without dalteparin in treating advanced breast, lung, colorectal, and prostate cancer. PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of standard therapy with or without dalteparin in treating patients who have advanced breast, lung, colorectal, or prostate cancer that has not responded to previous chemotherapy or hormone therapy.
Study identification
- NCT ID
- NCT00003674
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 141 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 1998
- Primary completion
- Mar 31, 2004
- Completion
- Mar 31, 2004
- Last update posted
- Jul 12, 2016
1998 – 2004
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Scottsdale Oncology Program | Scottsdale | Arizona | 85259-5404 | — |
| CCOP - Carle Cancer Center | Urbana | Illinois | 61801 | — |
| CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa | 52403-1206 | — |
| CCOP - Iowa Oncology Research Association | Des Moines | Iowa | 50309-1016 | — |
| Siouxland Hematology-Oncology | Sioux City | Iowa | 51101-1733 | — |
| CCOP - Wichita | Wichita | Kansas | 67214-3882 | — |
| CCOP - Ochsner | New Orleans | Louisiana | 70121 | — |
| CCOP - Ann Arbor Regional | Ann Arbor | Michigan | 48106 | — |
| CCOP - Duluth | Duluth | Minnesota | 55805 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| CentraCare Clinic | Saint Cloud | Minnesota | 56303 | — |
| CCOP - Missouri Valley Cancer Consortium | Omaha | Nebraska | 68131 | — |
| Medcenter One Health System | Bismarck | North Dakota | 58501 | — |
| CCOP - Merit Care Hospital | Fargo | North Dakota | 58122 | — |
| Altru Health Systems | Grand Forks | North Dakota | 58201 | — |
| CCOP - Toledo Community Hospital Oncology Program | Toledo | Ohio | 43623-3456 | — |
| CCOP - Geisinger Clinic and Medical Center | Danville | Pennsylvania | 17822-2001 | — |
| Rapid City Regional Hospital | Rapid City | South Dakota | 57709 | — |
| CCOP - Sioux Community Cancer Consortium | Sioux Falls | South Dakota | 57105-1080 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 12, 2016 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003674 live on ClinicalTrials.gov.